October 21, 2023

Eli Lil­ly is bol­ster­ing the case for its ex­per­i­men­tal eczema treat­ment le­brik­izum­ab with a first look at how pa­tients fared af­ter two years of main­te­nance

The Eu­ro­pean Com­mis­sion on Thurs­day an­nounced a first for its reg­u­la­tion of the phar­ma in­dus­try: It’s fin­ing five phar­ma com­pa­nies — Al­ka­loids of Aus­tralia, Al­ka­loids

Pfiz­er on Fri­day won ap­proval for its next mass-mar­ket vac­cine, a pen­tava­lent meningo­coc­cal vac­cine cov­er­ing the most com­mon serogroups in­fect­ing chil­dren and young adults ages

Re­pub­li­cans on the House En­er­gy and Com­merce Com­mit­tee are de­mand­ing that the NIH hand over more de­tails on its mpox re­search, ac­cord­ing to a let­ter

In a com­men­tary pub­lished Thurs­day, sev­er­al top FDA of­fi­cials of­fered in­sight in­to a key ques­tion when it comes to con­duct­ing clin­i­cal tri­als: How should re­al-world

In­di­an API man­u­fac­tur­er Nec­tar Life­sciences late last month re­ceived an un­ti­tled let­ter from the FDA over re­peat GMP vi­o­la­tions, the FDA said, fol­low­ing a sev­en-day

Eli Lil­ly took le­gal ac­tion on Thurs­day to stop for­eign im­porters and do­mes­tic dis­trib­u­tors from sell­ing and dis­trib­ut­ing wa­tered-down ver­sions of its block­buster type 2

MADRID — GSK has agreed to li­cense an an­ti­body-drug con­ju­gate from Han­soh Phar­ma for $85 mil­lion up­front, in ex­change for glob­al rights out­side of Chi­na,

Abi­vax start­ed trad­ing Fri­day on the Nas­daq, as the decade-old Paris-based start­up aims to raise about $236 mil­lion to get Phase III re­sults for its